Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents

Patent metadata

Field	Value
Publication number	US-12465640-B2
Application number	US-202017310802-A
Country	US
Kind code	B2
Filing date	Feb 25, 2020
Priority date	Feb 25, 2019
Publication date	Nov 11, 2025
Grant date	Nov 11, 2025

Abstract

The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases. Accordingly, embodiments of the disclosure relate to a composition comprising an anti-inflammatory agent operatively linked to an extracellular matrix (ECM)-affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to a serum protein and/or an ECM-affinity peptide. Further aspects of the disclosure relate to a method for treating an autoimmune or inflammatory condition in a subject comprising administering a composition of the disclosure to the subject.

First claim

The invention claimed is:

1 . A method for reducing inflammation in a subject comprising administering to the subject an effective amount of a composition comprising IL-10 linked to a peptide having at least 95% sequence identity to one of SEQ ID NOs: 3, 4, 5, 47, or 52.

2 . The method of claim 1 , wherein the inflammation comprises an inflammatory condition selected from the group consisting of inflammatory bowel disease, idiopathic pulmonary fibrosis, multiple sclerosis, type 1 diabetes, Crohn's disease, psoriasis, acute inflammation, chronic inflammation, neuroinflammation, and rheumatoid arthritis.

3 . The method of claim 1 , wherein the composition is administered systemically.

4 . The method of claim 3 , wherein the composition is administered by intravenous injection.

5 . The method of claim 1 , wherein the composition is administered locally.

6 . The method of claim 5 , wherein the composition is administered to or adjacent to a site of inflammation.

7 . The method of claim 1 , wherein the method further comprises administration of an additional inflammation therapy.

8 . The method of claim 1 , wherein the IL-10 linked to the peptide having 95% sequence identity to one of SEQ ID NOs: 3, 4, 5, 47, or 52 further comprises a serum protein linked to the peptide or IL-10.

9 . The method of claim 8 , wherein the serum protein comprises albumin.

10 . The method of claim 1 , wherein the ratio of peptide having 95% sequence identity to one of SEQ ID NOs: 3, 4, 5, 47, or 52 to the IL-10 is 1:1 to 5:1.

11 . The method of claim 2 , wherein the inflammatory condition comprises inflammatory bowel disease and wherein the inflammatory bowel disease is selected from Crohn's disease, autoimmune-mediated gastrointestinal diseases, colitis, and autoimmune inflammatory bowel disease.

12 . The method of claim 11 , wherein the colitis is selected from ulcerative colitis, colitis ulcerosa, microscopic colitis, collagenous colitis, colitis polyposa, necrotizing enterocolitis, and transmural colitis.

13 . The method of claim 1 , wherein the IL-10 is linked to a peptide having the amino acid sequence of one of SEQ ID NOs: 3, 4, 5, 47, or 52.

14 . The method of claim 1 , wherein the IL-10 is linked to a peptide having the amino acid sequence of SEQ ID NO:47.

15 . The method of claim 1 , wherein the IL-10 is linked to a peptide having the amino acid sequence of SEQ ID NO:52.

Assignees

• Univ Chicago

Inventors

• Hubbell Jeffrey A
• Katsumata Kiyomitsu
• Ishihara Ako
• Ishihara Jun
• Mansurov Aslan

Classifications

• A61K38/215

  IFN-beta · CPC title

• A61K38/2073

  IL-11 · CPC title

• A61K38/2066

  IL-10 · CPC title

• A61K38/2033

  IL-5 · CPC title

• A61K38/2026

  IL-4 · CPC title